COVID-19住院期间显著肝损伤与肝衰竭及死亡无关
该研究纳入834例 consecutive 住院COVID-19患者,发现12.6%发生显著肝损伤(AST≥5倍正常上限)。结论认为COVID-19相关肝酶异常继发于其他损伤,不导致肝衰竭或死亡。
要点
- COVID-19住院患者显著肝损伤发生率12.6%,主要与缺血和托珠单抗使用相关。
- 显著肝损伤与住院死亡无独立关联,而缺血、高凝、高炎症状态可预测死亡。
- AST与ALT强相关,但与INR和胆红素不相关,提示肝损伤不导致肝合成功能障碍。
核心结论
- COVID-19住院期间出现的显著肝损伤不导致肝衰竭或死亡,其肝酶异常继发于缺血或药物性肝损伤等其他因素。
研究设计与样本
- 回顾性队列研究,纳入834例 consecutive 住院COVID-19患者,收集入院及住院期间临床、用药和实验室数据。
主要发现
- 105例(12.6%)患者发生显著肝损伤(AST≥5倍正常上限)。
- AST与ALT密切相关(R=0.89),但与INR(R=0.10)和胆红素(R=0.09)不相关。
关键数值与推荐
- 显著肝损伤定义为AST≥5倍正常上限。
- 缺血定义为连续至少2天使用血管升压药。
- 高炎症状态定义为高敏C反应蛋白≥100 mg/L。
- 高凝状态定义为住院期间任何时间D-二聚体≥5 mg/L。
临床怎么用
- 对于COVID-19住院患者出现肝酶升高,应优先评估缺血、药物(如托珠单抗)等继发因素,而非直接归因于肝衰竭。
- AST显著升高但INR和胆红素正常时,提示肝合成功能未受明显影响,不必过度担心肝衰竭。
- 管理重点应关注缺血、高凝和高炎症状态,这些与死亡风险增加相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Coronavirus-19 disease (COVID-19) is associated with hepatocellular liver injury of uncertain significance. We aimed to determine whether development of significant liver injury during hospitalization is related to concomitant medications or processes common in COVID-19 (eg, ischemia, hyperinflammatory, or hypercoagulable states), and whether it can result in liver failure and death. METHODS: There were 834 consecutive patients hospitalized with COVID-19 who were included. Clinical, medication, and laboratory data were obtained at admission and throughout hospitalization using an identified database. Significant liver injury was defined as an aspartate aminotransferase (AST) level 5 or more times the upper limit of normal; ischemia was defined as vasopressor use for a minimum of 2 consecutive days; hyperinflammatory state was defined as high-sensitivity C-reactive protein value of 100 mg/L or more, and hypercoagulability was defined as D-dimer 5 mg/L or more at any time during hospitalization. RESULTS: A total of 105 (12.6%) patients developed significant liver injury. Compared with patients without significant liver injury, ischemia (odds ratio [OR], 4.3; range, 2.5-7.4; P < .0001) and tocilizumab use (OR, 3.6; range, 1.9-7.0; P = .0001) were independent predictors of significant liver injury. Although AST correlated closely with alanine aminotransferase (R = 0.89) throughout hospitalization, AST did not correlate with the international normalized ratio (R = 0.10) or with bilirubin level (R = 0.09). Death during hospitalization occurred in 136 (16.3%) patients. Multivariate logistic regression showed that significant liver injury was not associated with death (OR, 1.4; range, 0.8-2.6; P = .2), while ischemic (OR, 2.4; range, 1.4-4.0; P = .001), hypercoagulable (OR, 1.7; range, 1.1-2.6; P = .02), and hyperinflammatory (OR, 1.9; range, 1.2-3.1; P = .02) disease states were significant predictors of death. CONCLUSIONS: Liver test abnormalities known to be associated with COVID-19 are secondary to other insults, mostly ischemia or drug-induced liver injury, and do not lead to liver insufficiency or death.
引用
- Chew M, Tang Z, Radcliffe C, et al. Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death. Clin Gastroenterol Hepatol. 2021. PMID: 34004326. doi:10.1016/j.cgh.2021.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。